Innovate Biopharmaceuticals Acquires Late-stage Pancreatic Imaging Assets

Innovate Biopharmaceuticals, Inc. has entered into an agreement to purchase all assets related to a synthetic version of human secretin from Repligen Corporation. Repligen has completed a Phase 3 study demonstrating that its synthetic secretin improved detection of pancreatic duct abnormalities in patients with known or suspected pancreatitis. The acquisition includes a New Drug Application filedĀ  with the U.S Food and Drug Administration, a Marketing Authorization Application filed with the European Medicines Agency, and all related preclinical and clinical data and filings.

Jerry Gardner, M.D., Innovateā€™s Head of Clinical Strategy, is optimistic about the applications of the acquisition: ā€œSecretin, the first hormone, was discovered in 1902 based on its ability to stimulate pancreatic fluid and bicarbonate secretion. Its actions in the pancreatic-biliary system have the potential to improve identification by magnetic resonance imaging of structural abnormalities in this system including early cancer. Secretinā€™s actions in the central nervous system may influence food intake and possibly play a role in the treatment of cachexia and obesity.ā€

Read more about Innovateā€™s announcement, here.

get the latest